Handelsavisen
prelaunch
Companies Healthcare MAGLE.ST
MA
MAGLE.ST Nasdaq Stockholm Pharmaceuticals

Magle Chemoswed Holding AB

kr0,51
Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
14,9M SEK
P/E
EV / Rev
Div yield
0,00 %
Op margin
-44,9 %
ROE
-40,4 %
Net margin
-56,5 %
Debt / equity
0,87
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Magle Chemoswed Holding AB operates in the pharmaceuticals industry, focusing on the development and production of pharmaceutical products and related services.

Business. Magle Chemoswed Holding AB (MAGLE.ST) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-40,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MAGLE.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MAGLE.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Magle Chemoswed Holding AB (MAGLE.ST) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Sweden and is primarily listed on the Nasdaq Stockholm exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    Magle Chemoswed Holding AB has a market price of 3.56 SEK, with a market capitalization of 105,016,831.6 SEK, and a price-to-book ratio of 0.27, indicating a significant discount to its book value. The company's liquidity position is characterized by a current ratio of 1.37, suggesting it has sufficient short-term assets to cover its liabilities, but its cash and equivalents of 13,593,000 SEK are insufficient to cover its long-term debt of 346,187,000 SEK, resulting in a negative net cash position.

    Profitability metrics show a return on equity of -40.39% and a return on assets of -17.55%, both significantly below industry norms, indicating poor capital efficiency and operational performance. The company reported a net loss of 159,884,000 SEK and an operating loss of 126,963,000 SEK, with a gross profit of 232,427,000 SEK, suggesting high operating costs relative to revenue.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, which increases exposure to regional economic or regulatory risks. The lack of segmental or geographic breakdown in the financial data limits the ability to assess diversification benefits or concentration risks.

    Looking ahead, the company is expected to see a revenue increase to 345,000,000 SEK, a 21.96% year-over-year growth, according to analyst estimates. However, the operating cash flow of -31,930,000 SEK and free cash flow of -72,227,000 SEK indicate ongoing cash burn, which could constrain growth initiatives or necessitate external financing.

    The company faces liquidity and dilution risks, with a debt-to-equity ratio of 0.87 and a negative net cash position. Analysts have assigned a medium liquidity risk rating, and the company's dilution risk is currently low, with no near-term pressure expected. However, the negative operating cash flow and free cash flow suggest potential future dilution if the company requires additional capital.

    Recent financial filings and transcripts indicate that the company is in a development phase, with a focus on product innovation and market expansion. The company's current financial performance, including a net loss and negative cash flows, suggests that it is not yet generating sustainable profits and may require continued investment to achieve long-term growth.

    Key takeaways
    • Magle Chemoswed Holding AB is trading at a significant discount to book value, with a price-to-book ratio of 0.27.
    • The company is unprofitable, with a return on equity of -40.39% and a net loss of 159,884,000 SEK.
    • Analysts expect a 21.96% year-over-year revenue increase to 345,000,000 SEK, but the company is currently burning cash.
    • The company has a negative net cash position and a debt-to-equity ratio of 0.87, indicating moderate leverage.
    • The company's revenue is concentrated in a single segment, with no geographic diversification disclosed.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    kr0,51
    Market cap
    kr105.0M
    Enterprise value
    kr437.6M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.3x
    P / Tangible book
    0.3x
    Tangible book
    kr395.8M
    Net cash
    -kr332.6M
    Current ratio
    1.4
    Debt / equity
    0.9
    ROA
    -17.5%
    ROE
    -40.4%
    Cash conversion
    20.0%
    CapEx / revenue
    -4.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1,40
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate1,40
    Revenueno estimateno estimate345,0M SEK
    Operating incomeno estimateno estimate37,0M SEK
    Full-year consensus mean (period as reported by source) · consensus in SEK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    12-month price targetkr25,00 · Median kr25,00
    Low kr25,00High kr25,00
    Operating income · consensus37,0M SEK
    EPS surprise
    −652,9 %
    reported vs consensus · miss
    Revenue surprise
    −18,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Lowkr25,00
    Meankr25,00
    Mediankr25,00
    Highkr25,00
    Spotkr0,51
    +4850.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-44,9 %Bottom quartile
    Net Margin-56,5 %Bottom quartile
    ROE-40,4 %Bottom quartile
    Capex / Rev-4,5 %Above median
    D/E0,87Bottom quartile
    Cash Conv0,20Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Magle Chemoswed Holding AB Market data — financials · 2026-05-28
    • Magle Chemoswed Holding AB Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MAGLE.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage